Comparative Pharmacology
Head-to-head clinical analysis: DRAXIMAGE DTPA versus TECHNESCAN HIDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRAXIMAGE DTPA versus TECHNESCAN HIDA.
DRAXIMAGE DTPA vs TECHNESCAN HIDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DRAXIMAGE DTPA (technetium Tc-99m pentetate) is a radiopharmaceutical that, after intravenous injection, distributes in the extracellular space and is cleared by glomerular filtration. It allows imaging of renal function and structure by emitting gamma radiation detectable by a gamma camera.
Technetium Tc-99m mebrofenin is a radiopharmaceutical that, after intravenous administration, is taken up by hepatocytes via organic anion transporting polypeptides (OATPs) and excreted into the bile canaliculi via multidrug resistance-associated protein 2 (MRP2). It allows scintigraphic evaluation of hepatobiliary function by emitting gamma radiation detectable by a gamma camera.
Diagnostic imaging: 3-5 mCi (111-185 MBq) IV for renal studies; 10-20 mCi (370-740 MBq) IV for lung perfusion imaging.
5 mCi (185 MBq) administered intravenously as a single dose for hepatobiliary imaging.
None Documented
None Documented
Terminal elimination half-life is approximately 1.6 hours (range 1.2-2.0 hours) in patients with normal renal function; prolonged in renal impairment (up to 50 hours in severe cases).
Terminal elimination half-life is approximately 1.5 hours (range 1-2 hours) in patients with normal hepatic function. In patients with hepatic impairment, half-life may be prolonged up to 4-6 hours.
Renal: 95% within 24 hours via glomerular filtration; biliary/fecal: <5%.
Primarily biliary excretion: 85-90% of administered dose is excreted into bile via the hepatobiliary system within 2 hours, with minimal renal elimination (<5%) and fecal excretion accounting for <2%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical